Metagenomi Therapeutics (MGX) FCF Margin (2023 - 2026)
Metagenomi Therapeutics' (MGX) quarterly FCF Margin came in at 1706.65% in Q1 2026, down 114620.0% year-over-year from N/an in Q1 2025, and down 182.46% quarter-over-quarter from 604.22% in Q4 2025.
Powered by 
Analysis
Metagenomi Therapeutics (MGX) FCF Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported FCF Margin for 4 consecutive years, with 1706.65% the latest figure, recorded in Q1 2026.
- On a quarterly basis, FCF Margin fell 114620.0% year-over-year to 1706.65% in Q1 2026; TTM through Mar 2026 was 392.44%, a 16145.0% decrease from a year earlier, with the FY2025 full-year figure at 354.88%, down 14036.0% from the prior year.
- FCF Margin was 1706.65% for Q1 2026 at Metagenomi Therapeutics, down from 604.22% in the prior quarter.
- Over five years, FCF Margin peaked at 134.82% in Q2 2024 and troughed at 1706.65% in Q1 2026.
- A 4-year average of 401.49% and a median of 257.93% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin surged 12312 bps in 2024 and plunged 114620 bps in 2026, its largest moves.
- Over 4 years, FCF Margin stood at 180.09% in 2023, then slumped by 54 bps to 276.78% in 2024, then plunged by 118 bps to 604.22% in 2025, then sank by 182 bps to 1706.65% in 2026.
- The last three FCF Margin figures came in at 1706.65% (Q1 2026), 604.22% (Q4 2025), and 246.3% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 59.74% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | -826.50% |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -66.71% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -3.46% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | -497.31% |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | -13,981.63% |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | -33.11% |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 48.98% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 18.67% |
| 10 | Metagenomi Therapeutics | 44.20 Mn | 44.20 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,706.65% |
| Dec 31, 2025 | -604.22% |
| Sep 30, 2025 | -246.30% |
| Jun 30, 2025 | -251.12% |
| Mar 31, 2025 | -560.46% |
| Dec 31, 2024 | -276.78% |
| Sep 30, 2024 | -241.78% |
| Jun 30, 2024 | -134.82% |
| Mar 31, 2024 | -275.70% |
| Dec 31, 2023 | -180.09% |
| Sep 30, 2023 | -210.22% |
| Jun 30, 2023 | -257.93% |
| Mar 31, 2023 | -273.34% |